Insider buying last 90 days
No open-market insider purchases were filed for BCRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BCRX insider filing, plotted on the chart in Gekko.Open BCRX in Gekko
NASDAQ: BCRX
BioCryst Pharmaceuticals (BCRX) Stock Analysis & Forecast
Oct 12 close
$8.36−0.19 (−2.2%)
Gekko Brief
AI summaryOct 12 closeThis week's news for BioCryst centers on the formation of a seven-member Scientific Advisory Board of rare disease leaders to guide pipeline and external innovation work, alongside continued analyst commentary following Q2 2026 results. BofA Securities maintained a Buy rating with a $15 price target, while RBC Capital maintained a Hold rating with an $11 target. Coverage also referenced Q2 2026 revenue up 33.60% year over year to $218.25 million, with ORLADEYO sales and a licensing payment cited as drivers, and noted other analyst activity from JPMorgan, Needham and Wedbush.
BCRX closed at $8.36, down 2.2%, sitting below both its 50-day average of $9.09 and its 200-day average of $9.31. The stock's one-month return is 3%, while its three-month and six-month returns stand at -14.2% and -11.2%. The GekkoIndex reads 60, placing BCRX in the Accumulation zone, down 6.9 over five days. Price sits 35.9% below Gekko Fair Value of $13.04.
The next earnings date falls on 2 November 2026, before the open, within the coming 20 trading days; the prior report showed EPS of $0.30 against a $0.14 estimate with a 3.1% reaction, and BioCryst has beaten estimates in 5 of 8 recent quarters, with an average absolute reaction of 11%. Seasonality over this calendar window has averaged -6.8% across 4 years, rising in 1 of them. Analyst consensus across 8 firms shows 6 Buy and 2 Hold ratings, with a consensus target of $20.73.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
BioCryst Pharmaceuticals price vs fair value
Close $8.36200-day averageGekko Fair Value $13.04
BioCryst Pharmaceuticals quick facts
- Market cap
- $2.12B
- P/E ratio
- —
- Forward P/E
- 14.5
- EPS, TTM
- −$1.40
- Revenue, TTM
- $940.6M
- Profit margin
- -40.9%
- Dividend yield
- —
- Beta
- 0.55
- Volume
- 3.46M avg 5.44M
- 1-year return
- −1.3%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±9%
- 50-day average
- $9.09
- 200-day average
- $9.31
- Next earnings
- Nov 2 before open
- Shares outstanding
- 255.5M
BioCryst Pharmaceuticals swing-trade checklist
BioCryst Pharmaceuticals scores 2 supportive, 0 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed3 headwinds
- Trendheadwind
Below 50 and 200-day
Close $8.36 is below the 50-day ($9.09) and 200-day ($9.31) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
60, Accumulation
Reading 60 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
35.9% below
Price is 35.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 21 days
Reports on Nov 2, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.8% on average
From this point in the calendar, the next 20 trading days averaged −6.8% over 4 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BioCryst Pharmaceuticals stock chart and price history
BioCryst Pharmaceuticals closed at $8.36 on Oct 12, 2026, −1.3% over the past year, inside a 52-week range of $6.02 to $11.31.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.0%
- 3 months
- −14.2%
- 6 months
- −11.2%
- 1 year
- −1.3%
The full BCRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BCRX in Gekko
Follow BioCryst Pharmaceuticals through every session
Put BCRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BCRX in GekkoFree for 7 days. No credit card required.
BioCryst Pharmaceuticals GekkoIndex: the smart money zone
BioCryst Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60, in the Accumulation zone, down 6.9 points over five sessions.
60Accumulation
Down 6.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +4.1% | +18.8% | ||
| Accumulation (current zone) | 167 | +0.9% | +5.8% | ||
| Neutral | 308 | +0.2% | −0.3% | ||
| Distribution | 16 | −2.4% | −2.8% | ||
| Selling | 1 | Too few readings yet | |||
Average BCRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BCRX price, zone by zone.Track BCRX in Gekko
Is BioCryst Pharmaceuticals stock overvalued? Gekko Fair Value
BioCryst Pharmaceuticals trades 35.9% below Gekko Fair Value of $13.04, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BioCryst Pharmaceuticals shares are worth, recalculated every trading day.
$13.04
Gekko Fair Value, Oct 10, 2026
35.9% Undervalued
At the end of Aug 2026 the price was 42.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BCRX in Gekko
BioCryst Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for BioCryst Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BCRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BCRX, plotted on the chart in Gekko.Open BCRX in Gekko
Buybacks
BioCryst Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2023
- $2.17M
- As a share of market cap
- 0.10%
From company filings.
BioCryst Pharmaceuticals earnings: next date and track record
BioCryst Pharmaceuticals reports on Nov 2, 2026, before the open (21 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 21 days away
- EPS estimate
- $0.09
- Revenue estimate
- $165.7M
5 of 8reports beat the EPS estimate
±11%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- BioCryst reported Q2 2026 results featuring growing ORLADEYO revenue and disciplined spending driving increased cash generation. The company completed integration of Astria Therapeutics and launched ORLADEYO oral pellets for pediatric patients, receiving 47 prescriptions ahead of full-year expectations. Paid therapy rate improved to 84% vs. 83% year-ago. Management discontinued internal drug discovery to redirect resources toward external pipeline assets in rare diseases.
- Guidance
- Navenibart ALPHA-ORBIT pivotal trial top-line data expected Q3 2027. BCX17725 Netherton syndrome proof-of-concept data anticipated by end of 2026. Company will pursue external asset acquisitions to build balanced rare disease pipeline following Birmingham research unit closure.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.30 est $0.14 | $218.3M est $183.3M | +3.1% |
| May 6, 2026 | $0.14 est $0.11 | $156.4M est $151.1M | −1.4% |
| Feb 26, 2026 | $1.12 est $0.07 | $406.6M est $151.3M | +15.9% |
| Nov 3, 2025 | $0.06 est $0.07 | $159.4M est $151.3M | −13.1% |
| Aug 4, 2025 | $0.04 est $0.03 | $163.4M est $149.8M | −13.1% |
| May 5, 2025 | $0.00 est −$0.07 | $145.5M est $149.7M | +15.0% |
| Feb 24, 2025 | −$0.13 est −$0.06 | $131.5M est $126.6M | −10.1% |
| Nov 4, 2024 | −$0.07 est −$0.06 | $117.1M est $127.7M | −16.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BioCryst Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for BioCryst Pharmaceuticals is $20.73, +148.0% from the last close, from 8 firms rating the stock in the last 90 days.
$20.73consensus 12-month target, +148.0% from the last close
Now $8.36Avg $20.73
Low $11High $32
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 9 | Bank of America Securities | $15 | +79.4% |
| Oct 8 | RBC Capital | $11 | +31.6% |
| Sep 30 | J.P. Morgan | $13 | +55.5% |
| Sep 8 | Needham | $16 | +91.4% |
| Aug 10 | Evercore ISI | $17 | +103.3% |
+5.8%average 20-day move after past Accumulation readings
−6.8%average move over the next 20 trading days in the last 4 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BioCryst Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, BioCryst Pharmaceuticals averaged −6.8% across the last 4 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 2 of 4 |
| Next 10 trading days | +2.0% | 3 of 4 |
| Next 15 trading days | +1.2% | 2 of 4 |
| Next 20 trading days | −6.8% | 1 of 4 |
| Next 30 trading days | −10.5% | 1 of 4 |
For scale, BCRX’s typical 20-trading-day move in either direction is about 9%.
BioCryst Pharmaceuticals market cap and key statistics
BioCryst Pharmaceuticals’s market cap is $2.12B and revenue of $940.6M over the last twelve months.
Valuation
- Market cap
- $2.12B
- Forward P/E
- 14.5
- EPS, TTM
- −$1.40
- Gekko Fair Value
- $13.04
Trading
- Volume
- 3.46M
- Avg volume, 20 days
- 5.44M
- 52-week high
- $11.31
- 52-week low
- $6.02
- Shares outstanding
- 255.5M
Financials
- Revenue, TTM
- $940.6M
- Profit margin
- -40.9%
- Return on equity
- -1925%
- Quarterly earnings growth, YoY
- +1,400.0%
Risk and income
- Beta
- 0.55
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±9%
BioCryst Pharmaceuticals stock news this week
Coverage of BioCryst Pharmaceuticals this week reads positive: 8 positive, 4 neutral and 1 negative headlines.
- BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15Moomoo, Oct 10
- People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease LeadersBioBuzz, Oct 9
- RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11Moomoo, Oct 9
- BioCryst stock trades 1.47 percent below its prior close ahead of resultsAD HOC NEWS, Oct 8
- BioCryst Pharmaceuticals (BCRX) Names Scientific Advisory Board, Is The Discount Too Wide?Simply Wall Street, Oct 8
- BioCryst Pharmaceuticals stock fell 1.85 percent on October 6AD HOC NEWS, Oct 7
BioCryst Pharmaceuticals peers
BioCryst Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
BioCryst Pharmaceuticals stock FAQ
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $2.12B at the Oct 12, 2026 close of $8.36, with 255.5M shares outstanding.
What is the BioCryst Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for BioCryst Pharmaceuticals is $20.73, +148.0% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BioCryst Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate BioCryst Pharmaceuticals is undervalued: the Oct 12, 2026 close of $8.36 is 35.9% below Gekko Fair Value of $13.04. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BioCryst Pharmaceuticals report earnings next?
BioCryst Pharmaceuticals is expected to report on Nov 2, 2026, before the market opens (21 days away). Analysts expect earnings of $0.09 per share on revenue of $165.7M. BioCryst Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 11% on average across the report.
What is BioCryst Pharmaceuticals’s 52-week high and low?
BioCryst Pharmaceuticals’s 52-week high is $11.31 and its 52-week low is $6.02; it closed at $8.36 on Oct 12, 2026, −1.3% over the past year. Over the last five years the shares peaked at $19.99 on Feb 16, 2022.
Is BioCryst Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value) and 3 as headwinds (trend, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BioCryst Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.